BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HS-20118 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HS-20118\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07896915-1807@assetmemo.bio
DTSTAMP:20261121T005821Z
DTSTART;VALUE=DATE:20261225
DTEND;VALUE=DATE:20261226
SUMMARY:HS-20118: Phase 1 readout est. (NCT07896915)
DESCRIPTION:HS-20118\, phase 1.\nStudy: A Study to Evaluate the Pharmacokin
 etic Characteristics of HS-20118 Under Different Dosing Conditions in Heal
 thy Participants\nEstimated primary completion: 25 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/hs-20118#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07896915
URL:https://assetmemo.bio/drug/hs-20118#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07765628-1807@assetmemo.bio
DTSTAMP:20261121T005821Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:HS-20118: Phase 2 readout est. (NCT07765628)
DESCRIPTION:HS-20118\, phase 2\, Psoriasis.\nStudy: A Phase 2 Study of HS-2
 0118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-S
 evere Plaque Psoriasis\nEstimated primary completion: 28 February 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/hs-20118#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07765628
URL:https://assetmemo.bio/drug/hs-20118#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
